COX Share Price

Open 11.28 Change Price %
High 11.65 1 Day 0.29 2.59
Low 11.26 1 Week 0.32 2.86
Close 11.50 1 Month 1.46 14.54
Volume 122337 1 Year 1.05 10.05
52 Week High 13.68
52 Week Low 7.05
COX Important Levels
Resistance 2 11.86
Resistance 1 11.71
Pivot 11.47
Support 1 11.29
Support 2 11.14
EPA France Most Active Stocks
MT 4.53 12.97%
MT 4.53 12.97%
MT 4.53 12.97%
MT 4.53 12.97%
MT 4.53 12.97%
GSZ 17.56 3.97%
GSZ 17.56 3.97%
GSZ 17.56 3.97%
BRS 12.00 0.00%
BRS 12.00 0.00%
More..
EPA France Top Gainers Stocks
MLKRI 3.43 20.77%
APAM 33.78 15.72%
APAM 33.78 15.72%
MLLOI 3.80 15.15%
DEXB 17.47 13.89%
DEXB 17.47 13.89%
MT 4.53 12.97%
MT 4.53 12.97%
MT 4.53 12.97%
MT 4.53 12.97%
More..
EPA France Top Losers Stocks
ALDOL 15.00 -58.32%
MLATV 2.00 -33.33%
MLPHW 0.70 -21.35%
MLNEI 0.91 -16.51%
ALALO 0.08 -11.11%
MLAAE 4.49 -9.84%
MLHMC 3610.00 -8.38%
MLDEX 1.50 -7.41%
FED 12.55 -6.90%
FED 12.55 -6.90%
More..

Nicox (EPA: COX)

COX Technical Analysis 3
As on 23rd Jun 2017 COX Share Price closed @ 11.50 and we RECOMMEND Buy for LONG-TERM with Stoploss of 9.23 & Buy for SHORT-TERM with Stoploss of 10.53 we also expect STOCK to react on Following IMPORTANT LEVELS.
COX Target for June
1st Target up-side 14.97
2nd Target up-side 16.46
3rd Target up-side 17.94
1st Target down-side 10.73
2nd Target down-side 9.24
3rd Target down-side 7.76
COX Other Details
Segment EQ
Market Capital 0.00
Sector Healthcare
Industry Drug Manufacturers - Major
Offical website http://www.nicox.com
COX Address
COX
Drakkar 2 - B
2405 route des Dolines
Sophia Antipolis, 06906
France
Phone: 33 4 97 24 53 00
Fax: 33 4 97 24 53 99
COX Latest News
Interactive Technical Analysis Chart Nicox ( COX EPA France )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Nicox
COX Business Profile
NicOx S.A. develops a portfolio of therapies and diagnostic tools to enhance sight in the United States, Europe, and internationally. It provides AdenoPlus a diagnostic test that offers eyecare professionals to diagnose and manage patients with an acute red eye. The company’s pipeline product, Latanoprostene bunod, is in Phase III clinical trials for the treatment of glaucoma and ocular hypertension. In addition, it is engaged in the research and development of nitric oxide steroids for the treatment of back and front of the eye disease; and NO-donors for eye disorder applications. Further, the company develops Naproxcinod, an anti-inflammatory candidate that is in regulatory review with the US Food and Drug Administration for the treatment of signs and symptoms of osteoarthritis; nitric oxide for cardiovascular indications; and NCX 1047, a dermatology anti-inflammatory drug-candidate, which is in preclinical stage of development. NicOx S.A. has collaboration with Bausch + Lomb, Merck, and Grupo Ferrer Internacional S.A. The company was founded in 1996 and is headquartered in Sophia Antipolis, France.